17.1 Trapping of iodide by the following organ/organs is enhanced by thyrotropin:
A. Thyroid
B. Salivary gland
C. Placenta
D. All of the above
17.2 Triiodothyronine differs from thyroxine in that:
A. It is more avidly bound to plasma proteins
B. It has a shorter plasma half life
C. It is less potent
D. It has a longer latency of action
17.3 Metabolic rate of the following organ is not significantly affected by thyroxine:
A. Brain
B. Heart
C. Liver
D. Skeletal muscle
17.4 The most reliable guide to adjustment of thyroxine dose in a patient of hypothyroidism is:
A. Pulse rate
B. Body weight
C. Serum thyroxine level
D. Serum TSH level
17.5 Actions of thyroxine include the following except:
A. Induction of negative nitrogen balance
B. Reduction in plasma cholesterol level
C. Fall in plasma free fatty acid level
D. Rise in blood sugar level
17.6 Complications of over treatment with thyroxine include the following except:
A. Auricular fibrillation
B. Angina pectoris
C. Congestive heart failure
D. Acceleration of atherosclerosis
17.7 Thyroxine therapy is indicated in the following conditions except:
A. Euthyroid status with raised TSH level
B. Diffuse nontoxic goiter
C. Nonfunctional thyroid nodule
D. Benign functioning thyroid nodule
17.8 Triiodothyronine is preferred over thyroxine in the treatment of:
A. Endemic goiter
B. Cretinism
C. Papillary carcinoma of thyroid
D. Myxoedema coma
17.9 The following thyroid inhibitor does not produce goiter when given in over dose:
A. Propyl thiouracil
B. Carbimazole
C. Radioactive iodine
D. Sodium thiocyanate
17.10 Carbimazole acts by inhibiting:
A. Iodide trapping
B. Oxidation of iodide
C. Proteolysis of thyroglobulin
D. Synthesis of thyroglobulin protein
17.11 Antithyroid drugs exert the following action:
A. Inhibit thyroxine synthesis
B. Block the action of thyroxine on pituitary
C. Block the action of TSH on thyroid
D. Block the action of thyroxine on peripheral tissues
17.12 The following thyroid inhibitor interferes with peripheral conversion of thyroxine to triiodothyronine:
A. Propyl thiouracil
B. Methimazole
C. Carbimazole
D. Radioactive iodine
17.13 Overtreatment with the following thyroid inhibitor results in enlargement of the thyroid:
A. Lugol’s iodine
B. Radioactive iodine
C. Carbimazole
D. All of the above
17.15 Carbimazole differs from propylthiouracil in that:
A. It is dose to dose less potent
B. It has a shorter plasma half life
C. It does not produce an active metabolite
D. It does not inhibit peripheral conversion of
thyroxine to triiodothyronine
17.16 The thyroid inhibitor which produces the fastest response is:
A. Lugol’s iodine
B. Radioactive iodine
C. Propylthiouracil
D. Lithium carbonate
17.17 Choose the correct statement about carbimazole:
A. It induces improvement in thyrotoxic symptoms afer 1-4 weeks therapy
B. Control of thyrotoxic symptoms with carbimazole is accompanied by enlargement of thyroid gland
C. Its long term use in Grave's disease leads to ‘thyroid escape’
D. It mitigates thyrotoxic symptoms without lowering serum thyroxine levels
17.18 In the treatment of hyperthyroidism, carbimazole
has the following advantage over radioactive iodine:
A. Cost of treatment is lower
B. It is preferable in uncooperative patient
C. It is better tolerated by the patients
D. Hypothyroidism when induced is reversible
17.19 Lugol’s iodine is used in hyperthyroidism:
A. As long term definitive monotherapy
B. Preoperatively for 10-15 days
C. Postoperatively for 10-15 days
D. As adjuvant to carbimazole for long term therapy
17.20 The aim of iodine therapy before subtotal thyroidectomy in Grave’s disease is:
A. To render the patient euthyroid
B. To restore the iodine content of the thyroid gland
C. To inhibit peripheral conversion of thyroxine into triiodothyronine
D. To reduce friability and vascularity of the thyroid gland
17.21 The uses of sodium/potassium iodide include the
following except:
A. Preoperative preparation of Grave’s disease patient
B. Prophylaxis of endemic goiter
C. As antiseptic
D. As expectorant
17.22 The physical half life of radioactive 131I is:
A. 8 hours
B. 8 days
C. 16 days
D. 60 days
17.23 The most important drawback of radioactive iodine treatment of Grave’s disease is:
A. Subsequent hypothyroidism in many patients
B. Marked side effect for 1-2 weeks after treatment
C. High cost
D. Permanent cure cannot be achieved
17.24 Propranolol is used in hyperthyroidism:
A. As short-term symptomatic therapy till effect of carbimazole develops
B. As long-term therapy after subtotal thyroidectomy
C. In patients not responding to carbimazole
D. To potentiate the effect of radioactive iodine
17.25 Radioactive iodine is the treatment of choice for the following category of thyrotoxic patients:
A. Children
B. Young adults with recent oneset of Grave’s disease
C. Elderly patients with ischaemic heart disease
D. Pregnant women
17.1 A 17.2 B 17.3 A 17.4 D 17.5 C 17.6 D 17.7 C 17.8 D 17.9 C 17.10 B 17.11 A 17.12 A 17.13 C 17.15 D 17.16 A 17.17 A 17.18 D 17.19 B 17.20 D 17.21 C 17.22 B 17.23 A 17.24 A 17.25 C